James N. Topper, MD, PhD

James N. Topper, MD, PhD


Jamie Topper, M.D., Ph.D., has more than 25 years of experience working with entrepreneurs to found and build successful therapeutics-focused companies. He is a Managing General Partner of Frazier Healthcare Partners’ Life Sciences team. Throughout his 14 years as a General Partner, Jamie has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies.

Jamie has led and served as a board member for many of Frazier’s successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Calistoga Pharmaceuticals (co-founder, sold to Gilead Sciences), Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola (co-founder, NASDAQ: PTLA), CoTherix (sold to Actelion), and Threshold (NASDAQ: THLD). He currently represents Frazier on the boards of Allena Pharmaceuticals (NASDAQ: ALNA), Alpine Immune Sciences (NASDAQ: ALPN), Amunix Pharmaceuticals, AnaptysBio (NASDAQ: ANAB), Aptinyx (NASDAQ: APTX), and Phathom Pharmaceuticals. He is also a board observer for Alcresta Therapeutics and Sojournix.

Prior to joining Frazier, Jamie was the head of cardiovascular R&D at Millennium Pharmaceuticals and ran Millennium San Francisco (formerly COR Therapeutics). Before the merger of COR and Millennium, he served as the Vice President of Biology at COR and was responsible for all research activities. He served on the medical school faculties at Stanford and Harvard Medical School prior to joining COR.

Jamie received his M.D. and Ph.D. in Biophysics from Stanford and holds a B.S. from the University of Michigan.